fertduo.blogg.se

1. #EOT WOFF TTF SVG CONVERTER HOW TO#
2. #EOT WOFF TTF SVG CONVERTER PRO#
3. #EOT WOFF TTF SVG CONVERTER FREE#

css and web font files you don't plan on using.Ĭopy webfonts and CSS assets into one of your project directories Be sure to include the core styling file - /css/fontawesome.css - as well as the CSS files for any individual styles you want to use, and you can remove any.

#EOT WOFF TTF SVG CONVERTER FREE#

Just the Free Icons as Web Fonts to be used with CSSĬSS files for using just the Free Web FontsĬopy both the /webfonts and the /css folders into your project's static assets directory (or wherever you prefer to keep front-end assets or vendor stuff).

#EOT WOFF TTF SVG CONVERTER PRO#

There's a Free and Pro version of each in our Pro download - pick the one that's right for your project and grab those files. The /webfonts folder contains all of the typeface files that the CSS files depend on. The /css folder contains the core styling and utilities for all of Font Awesome's families (Classic, Sharp, and Brands) as well as style options (Solid, Regular, Light, Duotone, and Thin). Inside the Font Awesome Download or package, you'll find the files you need.

#EOT WOFF TTF SVG CONVERTER HOW TO#

Read more about how to correctly acknowledge RSC content. Permission is not required) please go to the Copyright If you want to reproduce the wholeĪrticle in a third-party commercial publication (excluding your thesis/dissertation for which If you are the author of this article, you do not need to request permission to reproduce figuresĪnd diagrams provided correct acknowledgement is given. Provided correct acknowledgement is given. If you are an author contributing to an RSC publication, you do not need to request permission Please go to the Copyright Clearance Center request page. To request permission to reproduce material from this article in a commercial publication, Provided that the correct acknowledgement is given and it is not used for commercial purposes. This article in other publications, without requesting further permission from the RSC, Cryan,Ĭreative Commons Attribution-NonCommercial 3.0 Unported Licence. Gene activated scaffolds incorporating star-shaped polypeptide-pDNA nanomedicines accelerate bone tissue regeneration in vivoĭ. Overall, this article describes for the first time the incorporation of novel star-polypeptide biomaterials carrying two therapeutic genes into a cell free scaffold which supports accelerated bone tissue formation in vivo. At the very early timepoint of just 4 weeks, we demonstrate the 64-star-PLL-pDual functionalised scaffold as a particularly efficient platform to accelerate bone tissue regeneration, with a 6-fold increase in new bone formation compared to a scaffold alone. In vivo, we demonstrate that a bone-mimetic, collagen-hydroxyapatite scaffold functionalized with star-PLLs containing either 32- or 64- poly( L-lysine) arms can be used to successfully deliver this pDual cargo to autologous host cells. The versatility of this polymeric vector is highlighted in its ability to transfect Mesenchymal Stem Cells (MSCs) with both osteogenic and angiogenic transgenes in a 3D environment from a range of scaffolds with various macromolecular compositions. In vitro, we demonstrate that star-PLL nanomaterials designed with 64 short poly( L-lysine) arms can be used to functionalise a range of collagen based scaffolds with a dual therapeutic cargo (pDual) of the bone-morphogenetic protein-2 plasmid (pBMP-2) and vascular endothelial growth factor plasmid (pVEGF). This is achieved via the in situ transfection of autologous host cells which migrate into the implanted collagen-based scaffold via gene-loaded, star-shaped poly( L-lysine) polypeptides (star-PLLs). This gene-loaded scaffold can accelerate bone tissue repair in vivo in comparison to a scaffold alone at just four weeks post implantation in a critical sized bone defect. Herein, we describe a cell-free, biocompatible and bioresorbable scaffold incorporating a novel star-polypeptide biomaterial as a gene vector. For example, significant clinical challenges still exist in efficiently healing large bone defects which are above a critical size. Increasingly, tissue engineering strategies such as the use of biomaterial scaffolds augmented with specific biological cues are being investigated to accelerate the regenerative process.